

Filed: March 10, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TEVA PHARMACEUTICALS USA, INC.,
Petitioner,

v.

INDIVIOR UK LIMITED,
Patent Owner.

Case IPR2016-00280
Patent 8,475,832

PETITIONER'S UPDATED EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Petitioner submits the following current exhibit list:

| Exhibit No. | Reference |
|-------------|---|
| 1001 | U.S. Patent No. 8,475,832 (filed August 7, 2009) |
| 1002 | File History, U.S. Patent No. 8,475,832 |
| 1003 | Expert Declaration of Nandita Das, Ph.D., Relating to U.S. Patent No. 8,475,832 |
| 1004 | U.S. Patent Application Publication 2005/0085440 (published April 21, 2005) (“Birch”) |
| 1005 | WO 2008/025791 (published March 6, 2008) (“Oksche”) |
| 1006 | U.S. Patent No. 7,357,891 (published December 23, 2004) (issued April 15, 2008) (“Yang”) |
| 1007 | WO 2008/040534 (published April 10, 2008) (“LabTec”) |
| 1008 | Suboxone® Label |
| 1009 | Suboxone® Tablet Summary Basis of Approval (“SBOA”) |
| 1010 | U.S. Patent Application Publication No. 2005/0037055 (“the ’055 publication”) |
| 1011 | European Medicines Agency Initial Marketing-Authorisation Document, Scientific Discussion, Oct. 19, 2006 for Suboxone sublingual tablets (“EMEA”) |
| 1012 | J.P. Cassidy et al., <i>Controlled Buccal Delivery of Buprenorphine</i> , 25 J. Controlled Release 21 (1993) |
| 1013 | Rex M. C. Dawson et al., <i>Data for Biochemical Research</i> (3d ed. 1986) |

| | |
|------|--|
| 1014 | Domenic A. Ciraulo et al., <i>Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials</i> , 46 J. Clinical Pharmacology 179 (2006) |
| 1015 | C. Nora Chiang & Richard L. Hawks, <i>Pharmacokinetics of the Combination Tablet of Buprenorphine and Naloxone</i> , 70 Drug & Alcohol Dependence S39 (2003) |
| 1016 | Campbell et al., <i>The History of the Development of Buprenorphine as an Addiction Therapeutic</i> , 1248 Ann. N.Y. Acad. Sc. (Issue: <i>Addiction Reviews</i>), 124 (2012) (“Campbell”) |
| 1017 | Bullingham et al., <i>Sublingual Buprenorphine Used Postoperatively: Clinical Observations and Preliminary Pharmacokinetic Analysis</i> , 12 Br. J. Clinical Pharmacology 117 (1981) |
| 1018 | U.S. Patent App. No. US 2010/0087470 |
| 1019 | U.S. Patent No. 4,582,835 |
| 1020 | Center for Drug Evaluation and Research, Approval Package for App. No. 22-410/S006/S007 (approval date 8/10/12) (“Film Approval Package”) |
| 1021 | Encyclopedia of Pharmaceutical Technology, 2 nd ed., Vol. I, Drug Delivery—Buccal Route (McElnay et al.) (“McElnay”) |
| 1022 | U.S. Patent No. 5,288,497 (“Stanley”) |
| 1023 | Declaration by Maureen Reitman, SC.D. (“Reitman Decl.”) |
| 1024 | Parkhurst A. Shore et al., <i>The Gastric Secretion of Drugs: A pH Partition Hypothesis</i> , 119 J. Pharmacology Exp. Ther. 361 (1957) |
| 1025 | Curriculum Vitae of Nandita Das, Ph.D. |
| 1026 | List of Materials Considered by Nandita Das, Ph.D. |
| 1027 | Telephone Conference Transcript, <i>Teva Pharmaceuticals USA, Inc. v. Monsol RX LLC and Indivior</i> , IPR2016-00280, IPR2016-00281, and IPR2016-00282 (Feb. 17, 2016) |
| 1028 | Declaration of Eleanor Yost in Support of Petitioner’s Motion to |

| | |
|------|--|
| | Correct Filing Date, IPR2016-00281, IPR2016-00282 |
| 1029 | Declaration of Linda Rogers in Support of Petitioner's Motion to Correct Filing Date, IPR2016-00281, IPR2016-00282 |
| 1030 | PRPS System Notification - Petition Submission IPR2016-00280 |
| 1031 | PRPS System Notification - Petition Submission IPR2016-00281 |
| 1032 | PRPS System Notification - Petition Submission IPR2016-00282 |
| 1033 | FedEx Location Website Printout (500 7 th Ave, New York, NY) |

CERTIFICATE OF SERVICE

The undersigned hereby certifies that the foregoing: **PETITIONER'S
UPDATED EXHIBIT LIST** was served electronically via e-mail on March 10,
2016 on the following:

Andrea G. Reister

areister@cov.com

Enrique D. Longton

rlongton@cov.com

Dated: March 10, 2016

By: /Cynthia Lambert Hardman/
Cynthia Lambert Hardman
(Reg. No. 53,179)